Quick Listen: Scrip's Five Must-Know Things
Executive Summary
In this week's podcast version of Five Must-Know Things: BMS’s new products meet early expectations; Eisai to shut a US unit in global R&D restructuring; Roche aims high for Vabysmo; US priority review for Biogen’s ALS contender; and a chat with Gennova’s CEO.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 29 July 2022, including: Bristol Myers Squibb Company’s new products meet early expectations; Eisai Co., Ltd. to shut a US unit in global R&D restructuring; Roche Holding AG aims high for Vabysmo; US priority review for Biogen, Inc.’s ALS contender; and a chat with Gennova Biopharmaceuticals Ltd’s CEO.
This and all our other podcasts are available on the Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "Bristol’s New Products Meet Early Launch Expectations" - Scrip, 27 Jul, 2022.)
(Also see "Eisai To Shut Down H3 In Global R&D Restructuring" - Scrip, 25 Jul, 2022.)
(Also see "Roche Is ‘Aiming For The Sky’ With Vabysmo Commercial Launch" - Scrip, 21 Jul, 2022.)
(Also see "Biogen ALS Drug Granted FDA Priority Review, Triggering Aduhelm Déjà Vu" - Scrip, 26 Jul, 2022.)
(Also see "CEO Of India's mRNA Pioneer Gennova On Cancer Vaccines, VC Interest" - Scrip, 27 Jul, 2022.)